PSMA Targeted Ligands in Imaging and Theranostics for Prostate Cancer

被引：1

作者：

Sen, Bilge ^{[1
]}

Ozkan, Elgin ^{[2
]}

Kucuk, Nuriye Ozlem ^{[2
]}

机构：

[1] Ankara Univ Inst Hlth Sci, Fac Pharm, Dept Dept Analyt Chem, Ankara, Turkiye

[2] Ankara Univ Fac Med, Deparment Nucl Med, Ankara, Turkiye

来源：

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2023年 / 22卷 / 04期

关键词：

PET imaging; prostate cancer; theranostics; I-AND-T; MEMBRANE ANTIGEN-EXPRESSION; RADIATION-DOSIMETRY; RADIOLIGAND THERAPY; BIOCHEMICAL RECURRENCE; PRECLINICAL EVALUATION; BONE-SCINTIGRAPHY; LYMPH-NODES; PET; BIODISTRIBUTION;

D O I：

10.4274/uob.galenos.2023.2023.8.2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PCa) is the second most common type of cancer in men. Compared with conventional imaging methods, prostate-specific membrane antigen (PSMA)-targeted positron emission tomography has higher accuracy and specificity for the detection and treatment of PCa. Through targeted imaging, ligands are labelled with 18F, 68Ga, or 64Cu, and the disease is staged and managed more accurately. It is also desirable to use PSMA-targeted theranostics that are labelled with either imaging radioisotopes or treatment isotopes such as 177Lu, 225Ac, 131I. Here, we summarized some of the commonly used small molecule PSMA ligands for imaging and theranostic purposes.

引用

页码：129 / 137

页数：9

共 76 条

[1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[2] The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kratochwil, Clemens ;

Benesova, Martina ;

Eder, Matthias ;

Neels, Oliver C. ;

Eisenhut, Michael ;

Kuebler, Wolfgang ;

Holland-Letz, Tim ;

Giesel, Frederik L. ;

Mier, Walter ;

Kopka, Klaus ;

Haberkorn, Uwe .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705

[3] PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer [J].

Afshar-Oromieh, Ali ;

Haberkorn, Uwe ;

Hadaschik, Boris ;

Habl, Gregor ;

Eder, Matthias ;

Eisenhut, Michael ;

Schlemmer, Heinz-Peter ;

Roethke, Matthias C. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (10) :1629-1630

[4] Comparison between malignant and benign abdominal lymph nodes on diffusion-weighted imaging [J].

Akduman, E. Isin ;

Momtahen, Amir Javad ;

Balci, N. Cem ;

Mahajann, Namit ;

Havlioglu, Necat ;

Wolverson, Michael K. .

ACADEMIC RADIOLOGY, 2008, 15 (05) :641-646

[5] 68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer [J].

Banerjee, Sangeeta Ray ;

Pullambhatla, Mrudula ;

Byun, Youngjoo ;

Nimmagadda, Sridhar ;

Green, Gilbert ;

Fox, James J. ;

Horti, Andrew ;

Mease, Ronnie C. ;

Pomper, Martin G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5333-5341

[6] First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer [J].

Barrett, John A. ;

Coleman, R. Edward ;

Goldsmith, Stanley J. ;

Vallabhajosula, Shankar ;

Petry, Neil A. ;

Cho, Steve ;

Armor, Thomas ;

Stubbs, James B. ;

Maresca, Kevin P. ;

Stabin, Michael G. ;

Joyal, John L. ;

Eckelman, William C. ;

Babich, John W. .

JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) :380-387

[7] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

[8]

Behe M, 2011, IN VIVO, V25, P55

[9] Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer [J].

Behr, Spencer C. ;

Aggarwal, Rahul ;

VanBrocklin, Henry F. ;

Flavell, Robert R. ;

Gao, Kenneth ;

Small, Eric J. ;

Blecha, Joseph ;

Jivan, Salma ;

Hope, Thomas A. ;

Simko, Jeffry P. ;

Kurhanewicz, John ;

Noworolski, Susan M. ;

Korn, Natalie J. ;

De Los Santos, Romelyn ;

Cooperberg, Matthew R. ;

Carroll, Peter R. ;

Nguyen, Hao G. ;

Greene, Kirsten L. ;

Langton-Webster, Beatrice ;

Berkman, Clifford E. ;

Seo, Youngho .

JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) :910-916

[10] Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].

Benesova, Martina ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Afshar-Oromieh, Ali ;

Kratochwil, Clemens ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920

← 1 2 3 4 5 6 7 8 →